S6k1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancer

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Nawroth, Roman ^a   Stellwagen, Florian ^a   Schulz, Wolfgang A ^c   Stoehr, Robert ^b   Hartmann, Arndt ^b   Krause, Bernd J ^d   Gschwend, Juergen E ^a   Retz, Margitta ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PHOSPHATASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEINASE INHIBITOR; S6 KINASE; S6 KINASE 1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; 1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; DRUG DERIVATIVE; EIF4EBP1 PROTEIN, HUMAN; EVEROLIMUS; IMIDAZOLE DERIVATIVE; PHOSPHOPROTEIN; QUINOLINE DERIVATIVE; RAPAMYCIN; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE; TEMSIROLIMUS;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL ACTIVATION; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME INHIBITION; MOLECULAR INTERACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; BLADDER TUMOR; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METASTASIS; PATHOLOGY; TIME; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; APOPTOSIS; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHOPROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; URINARY BLADDER NEOPLASMS;

EID: 81055144867     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027509     Document Type: Article

References (56)

1. Ehdaie B, Smith SC, Theodorescu D, (2009) Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat. Can Urol Assoc J 3: S232-236.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
3. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, et al. (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19: 666-675.
4. Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG, (2006) Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 176: 486-492; discussion 491-482.
5. von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, et al. (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23: 4602-4608.
6. Zachos I, Konstantinopoulos PA, Tzortzis V, Gravas S, Karatzas A, et al. (2010) Systemic therapy of metastatic bladder cancer in the molecular era: current status and future promise. Expert Opin Investig Drugs 19: 875-887.
7. Wu XR, (2009) Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev 28: 281-290.
8. Cheng L, Davidson DD, Maclennan GT, Williamson SR, Zhang S, et al. (2010) The origins of urothelial carcinoma. Expert Rev Anticancer Ther 10: 865-880.
9. Engelman JA, (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
10. Bai X, Jiang Y, (2009) Key factors in mTOR regulation. Cell Mol Life Sci.
11. Manning BD, Cantley LC, (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
12. Chiang GG, Abraham RT, (2007) Targeting the mTOR signaling network in cancer. Trends Mol Med 13: 433-442.
13. LoPiccolo J, Granville CA, Gills JJ, Dennis PA, (2007) Targeting Akt in cancer therapy. Anticancer Drugs 18: 861-874.
14. Ma XM, Blenis J, (2009) Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318.
15. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, et al. (2010) 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18: 39-51.
16. Richter JD, Sonenberg N, (2005) Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433: 477-480.
17. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, et al. (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065-3074.
18. Zhang J, Gao Z, Yin J, Quon MJ, Ye J, (2008) S6K directly phosphorylates IRS-1 on Ser-270 to promote insulin resistance in response to TNF-(alpha) signaling through IKK2. J Biol Chem 283: 35375-35382.
19. Iijima Y, Laser M, Shiraishi H, Willey CD, Sundaravadivel B, et al. (2002) c-Raf/MEK/ERK pathway controls protein kinase C-mediated p70S6K activation in adult cardiac muscle cells. J Biol Chem 277: 23065-23075.
20. Yujiri T, Nawata R, Takahashi T, Sato Y, Tanizawa Y, et al. (2003) MEK kinase 1 interacts with focal adhesion kinase and regulates insulin receptor substrate-1 expression. J Biol Chem 278: 3846-3851.
21. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, et al. (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.
22. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP, (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 121: 179-193.
23. Sabatini DM, (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729-734.
24. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, et al. (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7: 1851-1863.
25. Strimpakos AS, Karapanagiotou EM, Saif MW, Syrigos KN, (2009) The role of mTOR in the management of solid tumors: an overview. Cancer Treat Rev 35: 148-159.
26. Knowles MA, Platt FM, Ross RL, Hurst CD, (2009) Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev.
27. Mitra AP, Cote RJ, (2009) Molecular pathogenesis and diagnostics of bladder cancer. Annu Rev Pathol 4: 251-285.
28. Schultz L, Albadine R, Hicks J, Jadallah S, DeMarzo AM, et al. (2010) Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer 116: 5517-5526.
29. Gupta AK, Cerniglia GJ, Mick R, Ahmed MS, Bakanauskas VJ, et al. (2003) Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int J Radiat Oncol Biol Phys 56: 846-853.
30. Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, et al. (2004) The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 93: 143-150.
31. Wu D, Tao J, Xu B, Qing W, Li P, et al. (2011) Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells. Urol Int 86: 346-354.
32. Kim IA, Bae SS, Fernandes A, Wu J, Muschel RJ, et al. (2005) Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines. Cancer Res 65: 7902-7910.
33. Brachmann S, Fritsch C, Maira SM, Garcia-Echeverria C, (2009) PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 21: 194-198.
34. Fechner G, Classen K, Schmidt D, Hauser S, Muller SC, (2009) Rapamycin inhibits in vitro growth and release of angiogenetic factors in human bladder cancer. Urology 73: 665-668; discussion 668-669.
35. Le Tourneau C, Faivre S, Serova M, Raymond E, (2008) mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 99: 1197-1203.
36. Seager CM, Puzio-Kuter AM, Patel T, Jain S, Cordon-Cardo C, et al. (2009) Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila Pa) 2: 1008-1014.
37. Seront E, Sautois B, Rottey S, D'Hondt LA, Canon J, et al. (2011) Phase II trial of everolimus monotherapy in the palliative treatment of patients with metastatic transitional cell carcinoma (TCC) after failure of platinum-based therapy: Activity and biomarkers. J Clin Oncol 29.
38. Nawroth R, Poell G, Ranft A, Kloep S, Samulowitz U, et al. (2002) VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts. Embo J 21: 4885-4895.
39. Gomez-Roman JJ, Saenz P, Molina M, Cuevas Gonzalez J, Escuredo K, et al. (2005) Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth. Clin Cancer Res 11: 459-465.
40. Li C, Teng RH, Tsai YC, Ke HS, Huang JY, et al. (2005) H-Ras oncogene counteracts the growth-inhibitory effect of genistein in T24 bladder carcinoma cells. Br J Cancer 92: 80-88.
41. Platt FM, Hurst CD, Taylor CF, Gregory WM, Harnden P, et al. (2009) Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 15: 6008-6017.
42. Brunn GJ, Williams J, Sabers C, Wiederrecht G, Lawrence JC Jr, et al. (1996) Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002. EMBO J 15: 5256-5267.
43. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, et al. (2007) Exploring the specificity of the PI3K family inhibitor LY294002. Biochem J 404: 15-21.
44. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, et al. (2010) FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One 5: e13821.
45. Iwamaru A, Kondo Y, Iwado E, Aoki H, Fujiwara K, et al. (2007) Silencing mammalian target of rapamycin signaling by small interfering RNA enhances rapamycin-induced autophagy in malignant glioma cells. Oncogene 26: 1840-1851.
46. Willett M, Cowan JL, Vlasak M, Coldwell MJ, Morley SJ, (2009) Inhibition of mammalian target of rapamycin (mTOR) signalling in C2C12 myoblasts prevents myogenic differentiation without affecting the hyperphosphorylation of 4E-BP1. Cell Signal 21: 1504-1512.
47. Chapuis N, Tamburini J, Green AS, Vignon C, Bardet V, et al. (2010) Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin Cancer Res 16: 5424-5435.
48. Thoreen CC, Kang SA, Chang JW, Liu Q, Zhang J, et al. (2009) An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J Biol Chem 284: 8023-8032.
49. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM, (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101.
50. Dowling RJ, Topisirovic I, Alain T, Bidinosti M, Fonseca BD, et al. (2010) mTORC1-mediated cell proliferation, but not cell growth, controlled by the 4E-BPs. Science 328: 1172-1176.
51. Seront E, Rottey S, Sautois B, D'Hondt LA, Canon JR, et al. (2010) A single arm, multicenter, phase II trial of everolimus as monotherapy in the palliative treatment of patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy. Journal of Clinical Oncology 28: e15087.
52. Pal SK, Reckamp K, Yu H, Figlin RA, (2010) Akt inhibitors in clinical development for the treatment of cancer. Expert Opin Investig Drugs 19: 1355-1366.
53. Julien LA, Carriere A, Moreau J, Roux PP, (2010) mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol Cell Biol 30: 908-921.
54. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, et al. (2009) NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 8: 2204-2210.
55. Castellano E, Downward J, (2010) Role of RAS in the regulation of PI 3-kinase. Curr Top Microbiol Immunol 346: 143-169.
56. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.